<\/p>\n
On August 19, Merck (MRK) said its personalized cancer vaccine had proved effective in a large, late-stage melanoma study, and Wall Street responded fast. <\/p>\n
Merck shares closed up about 12.5% that day, one of the biggest single-day moves the stock has ever posted.<\/p>\n
The rally added roughly $43 billion to Merck’s market value in hours.<\/p>\n
The reason the market cared so much goes beyond one skin-cancer result. <\/p>\n
Merck faces a problem in 2028, when its top-selling drug loses patent protection. This new vaccine gives the company a way to replace some of that revenue.<\/p>\n
For investors, the question now is whether the jump reflects real long-term value or a one-day reaction that fades. <\/p>\n
What Merck’s Phase 3 melanoma result actually showed<\/p>\n
Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma – Merck.com↗<\/p>\n
Merck and partner Moderna (MRNA) said their Phase 3 INTerpath-001 trial hit its main goal.<\/p>\n
The study tested a vaccine called Intismeran alongside Merck’s blockbuster immunotherapy Keytruda in patients whose melanoma had been surgically removed.<\/p>\n
Intismeran is a personalized treatment. It reads the specific mutations in each patient’s tumor, then trains the immune system to recognize and attack cancer cells that carry them.<\/p>\n
The trial enrolled 1,137 people with high-risk, stage 2B to stage 4 melanoma, according to Moderna‘s release.<\/p>\n
More Health Care Stocks:<\/p>\n
JPMorgan sees 100% upside in overlooked cancer drug stock<\/p>\n
BofA biotech scorecard: Two buys and odd one out<\/p>\n
135-year-old healthcare giant surges on cancer vaccine breakthrough<\/p>\n
The combination of the two drugs beat Keytruda alone on two measures: how long patients went without their cancer returning, and how long before it spread to distant parts of the body.<\/p>\n
The companies called it the first positive Phase 3 result for an individualized mRNA cancer therapy.<\/p>\n
Why the $43 billion jump surprised even Wall Street<\/p>\n
The rally looks big compared to the actual melanoma sales at stake.<\/p>\n
Goldman Sachs analysts, in a research note shared with TheStreet, estimated global peak sales for Intismeran for treatment of melanoma at about $4.3 billion a year.<\/p>\n
Merck and Moderna will split the profits 50\/50, though Merck books all the global sales.<\/p>\n
So why did Merck add roughly $43 billion in market value over a program worth a few billion in annual sales? <\/p>\n
Investors were pricing in more than melanoma.<\/p>\n
The result validated the underlying technology, opening the door to using the same approach against other cancers.<\/p>\n
Goldman noted that Merck shares carried lower expectations for this program going in, which left more room for the stock to move once the data landed.<\/p>\n
Merck and Moderna’s personalized mRNA vaccine trains each patient’s immune system using mutations found in their own tumors.<\/p>\n
Cheng Xin \/ Getty Images<\/p>\n
The Keytruda cliff that makes this vaccine matter<\/p>\n
Keytruda is Merck’s best-selling drug and made up close to half of the company’s 2025 sales.<\/p>\n
That drug loses key U.S. patent protection in 2028, which means cheaper competition can enter, and revenue could drop sharply.<\/p>\n
Investors have worried for years about what replaces that income. Intismeran gives Merck a credible answer.<\/p>\n
Related: UBS strongly resets Lilly stock target<\/p>\n
A vaccine like Intismeran, tailored to each patient, is hard to copy, so it faces limited generic competition and could produce a longer, steadier revenue stream than a typical drug.<\/p>\n
That durability is what strengthened Wall Street confidence in Merck’s future progress, after 2028, when Keytruda loses exclusivity.<\/p>\n
How analysts reset their Merck price targets<\/p>\n
The data triggered a wave of higher price targets across Wall Street.<\/p>\n
Goldman Sachs raised its 12-month target on Merck to $160 from $140 and applied a higher earnings multiple, of 16 times, up from 14 times.<\/p>\n
Other firms moved in the same direction:<\/p>\n
UBS lifted its target to $175 from $145 and kept a Buy rating.<\/p>\n
Bank of America raised its target to $166 from $141.<\/p>\n
JPMorgan moved to $150.<\/p>\n
Not every analyst turned more bullish. <\/p>\n
RBC Capital downgraded Merck to Sector Perform, even while raising its target to $150, a reminder that a strong result can still leave a stock fully valued after a double-digit jump.<\/p>\n
What still has to happen for Merck<\/p>\n
The melanoma win is one indication. The bigger prize depends on results in other cancers, and those are still pending.<\/p>\n
For example, Merck is focusing the vaccine on tumors that respond well to immune-based treatment, such as melanoma and non-small cell lung cancer.<\/p>\n
Here is the near-term timeline investors are watching:<\/p>\n
Renal cell carcinoma (a kidney cancer): Phase 2 data expected in 2026 or early 2027<\/p>\n
Muscle-invasive bladder cancer: Phase 2 data in 2027<\/p>\n
Non-small cell lung cancer: Phase 3 data in 2027<\/p>\n
A win in kidney cancer would suggest the approach can work in the same settings where Keytruda already helps patients.<\/p>\n
The companies also plan to present full melanoma data at an international medical meeting and file submissions with regulators, according to Merck.<\/p>\n
Who else moved on the news<\/p>\n
The result lifted a group of related health care stocks in what traders call a sympathy move.<\/p>\n
BioNTech (BNTX), which runs its own personalized cancer vaccine programs, rose about 24% as investors saw the data as broad support for the approach.<\/p>\n
Companies tied to manufacturing and cancer diagnostics also jumped, including Maravai LifeSciences (MRVI), up about 28%, and Tempus AI (TEM), up about 24%.<\/p>\n
Investors watched Bristol-Myers Squibb (BMY), a major player in melanoma treatment, for risk.<\/p>\n
Goldman estimated a long-term risk of up to $1 billion to Bristol’s melanoma franchise, but expects the impact to be limited and gradual.<\/p>\n
This is because Intismeran targets earlier-stage patients, while much of Bristol’s melanoma revenue comes from later-stage, metastatic cases.<\/p>\n
What Merck’s move means for your portfolio<\/p>\n
Merck’s rally reflects a real change in the company’s long-term outlook.<\/p>\n
For investors, a few things are worth keeping in mind:<\/p>\n
The stock already climbed sharply, so much of the good news is now in the price.<\/p>\n
The melanoma result is strong, but survival data is still early, and full results have not been published.<\/p>\n
The larger payoff depends on kidney, bladder, and lung cancer trials that report in 2026 and 2027.<\/p>\n
If those readouts succeed, Merck’s case for replacing Keytruda revenue gets much stronger.<\/p>\n
If they disappoint, the stock could give back some of this gain, which is why the coming trial dates matter more than the one-day rally.<\/p>\n
For long-term investors, Merck now offers a clearer story beyond its patent cliff, backed by a technology that just proved it can work.<\/p>\n
Related: Goldman Sachs sees writing on the wall for Eli Lilly stock<\/p>\n
#cancer #vaccine #years #making #proved<\/p>\n","protected":false},"excerpt":{"rendered":"
On August 19, Merck (MRK) said its personalized cancer vaccine had proved effective in a…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[259],"tags":[989,866,613,3329,84],"_links":{"self":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/14367"}],"collection":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14367"}],"version-history":[{"count":0,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/14367\/revisions"}],"wp:attachment":[{"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14367"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14367"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14367"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}